systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-391Research ArticleОБЗОРЫПериндоприл - ингибитор ангиотензинпревращающего фермента с самой большой доказательной базойPerindopril - angiotensin-converting enzyme inhibitor is approved for usageНапалковД. А.NapalkovD. A.noemail@neicon.ruГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РоссииRussian Federation2014231220221147578Copyright © Напалков Д.А., 20222022Напалков Д.А.Napalkov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/391

В форме литературного обзора изложена концепция подхода к лечению пациентов с артериальной гипертензией высокого риска, у которых применение ингибиторов АПФ является наиболее перспективным с позиции доказательной кардиологии. Одним из наиболее изученных препаратов является периндоприл. В статье приводятся данные по особым свойствам молекулы периндоприла, а также по возможности использования комбинаций периндоприла и индапамида, а также периндоприла и амлодипина для реализации их органопротективных свойств. В завершении предложен дифференцированный подход к использованию различных препаратов, содержащих периндоприл, по разным показаниям.

In the form of the literature review we shows the concept of the treatment of high-risk hypertensive patients, who have been taking ACE inhibitors which application is the most advanced approach from the perspective of evidence-based cardiology. One of the most studied drugs is perindopril. The article deals with the data on the special properties of perindopril molecules, as well as on the possibilities of using perindopril and indapamide combination, as well as on usage of indapamide and amlodipine for the realization of protective mechanism. At the conclusion of the article we offered the differentiated approach to the usage of different drugs containing perindopril for different indications.

артериальная гипертензияпериндоприлиндапамидамлодипинорганопротекцияarterial hypertensionperindoprilindapamideamlodipineorganoprotectionReferencesVan Vark L.C, Bertrand M, Akkerhuis K.M et al. Angiotensin - converting enzyme inhibitors reduce mortality in hypertension: a meta - analysis of randomized clinical trials of renin - angiotensin - aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33: 2088-97.Van Vark L.C, Bertrand M, Akkerhuis K.M et al. Angiotensin - converting enzyme inhibitors reduce mortality in hypertension: a meta - analysis of randomized clinical trials of renin - angiotensin - aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33: 2088-97.Напалков Д.А. Терапия периндоприлом: органопротекция, а не только антигипертензивный эффект. Кардиология. 2012; 12: 80-3.Напалков Д.А. Терапия периндоприлом: органопротекция, а не только антигипертензивный эффект. Кардиология. 2012; 12: 80-3.Ranadive S.A, Chen A.X, Serajuddin A.T. Relative lipophilicities and structural - pharmacological considerations of various angiotensin - converting enzyme inhibitors. Pharm Res 1992; 9 (11): 1480-6.Ranadive S.A, Chen A.X, Serajuddin A.T. Relative lipophilicities and structural - pharmacological considerations of various angiotensin - converting enzyme inhibitors. Pharm Res 1992; 9 (11): 1480-6.Ferrari R, Bertrand M.E, Remme W.J et al. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial. Expert Rev Cardiovasc Ther 2007; 5 (6): 1037-46.Ferrari R, Bertrand M.E, Remme W.J et al. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial. Expert Rev Cardiovasc Ther 2007; 5 (6): 1037-46.Mc Queen M.J, Lonn E, Gerstein H.C et al. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest Suppl 2005; 240: 143-56.Mc Queen M.J, Lonn E, Gerstein H.C et al. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest Suppl 2005; 240: 143-56.Borghi C, Bacchelli S, Esposti D.D et al. Effects of the administration of an angiotensin - converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long - term Evaluation. Am J Hypertens 1999; 12 (7): 665-72.Borghi C, Bacchelli S, Esposti D.D et al. Effects of the administration of an angiotensin - converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long - term Evaluation. Am J Hypertens 1999; 12 (7): 665-72.Heart Outcomes Prevention Evaluation Study Investigators: Effect of an angiotensin converting - enzyme inhibitor ramipril on cardiovascular events in high - risk patients. N Engl J Med 2000; 342: 145-53.Heart Outcomes Prevention Evaluation Study Investigators: Effect of an angiotensin converting - enzyme inhibitor ramipril on cardiovascular events in high - risk patients. N Engl J Med 2000; 342: 145-53.Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.Bertrand M.E, Fox K.M et al. Angiotensin - converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis 2009; 102 (2): 89-96.Bertrand M.E, Fox K.M et al. Angiotensin - converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis 2009; 102 (2): 89-96.Ceconi C, Fox K.M, Remme W.J et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237-46.Ceconi C, Fox K.M, Remme W.J et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237-46.PREAMI: perindopril and remodelling in elderly with acute myocardial infarction: study rationale and design. Cardiovasc Drugs Ther 2000; 14 (6): 671-9.PREAMI: perindopril and remodelling in elderly with acute myocardial infarction: study rationale and design. Cardiovasc Drugs Ther 2000; 14 (6): 671-9.Patel A, Mac Mahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370 (9590): 829-40.Patel A, Mac Mahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370 (9590): 829-40.Beckett I.S, Peters R, Fletcher A.E, Staessen J.A et al. for the HYVET study group. Treatment of hypertension in patients 80 years of age and older. N Engl J Med 2008; 358 (18): 1887-98.Beckett I.S, Peters R, Fletcher A.E, Staessen J.A et al. for the HYVET study group. Treatment of hypertension in patients 80 years of age and older. N Engl J Med 2008; 358 (18): 1887-98.PROGRESS Collaborative Group. Effects of a perindopril - based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475-84.PROGRESS Collaborative Group. Effects of a perindopril - based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475-84.Dahlöf B., Sever P.S, Poulter N.R et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906.Dahlöf B., Sever P.S, Poulter N.R et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906.Д.А.Напалков, А.В.Жиленко. Современные подходы к комбинированной терапии артериальной гипертензии. Системные гипертензии. 2013; 10 (4): 44-9.Д.А.Напалков, А.В.Жиленко. Современные подходы к комбинированной терапии артериальной гипертензии. Системные гипертензии. 2013; 10 (4): 44-9.Bertrand M.E. Perindopril/amlodipine combination: an optimal synergy for cardiovascular protection. Eur Heart J Suppl 2009; 11 (Suppl. E): E22-E25.Bertrand M.E. Perindopril/amlodipine combination: an optimal synergy for cardiovascular protection. Eur Heart J Suppl 2009; 11 (Suppl. E): E22-E25.

The authors declare that there are no conflicts of interest present.